Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 2
2009 1
2010 1
2011 2
2012 2
2013 3
2014 1
2015 2
2016 6
2017 6
2018 11
2019 4
2020 13
2021 16
2022 18
2023 15
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
TMPRSS2 is a functional receptor for human coronavirus HKU1.
Saunders N, Fernandez I, Planchais C, Michel V, Rajah MM, Baquero Salazar E, Postal J, Porrot F, Guivel-Benhassine F, Blanc C, Chauveau-Le Friec G, Martin A, Grzelak L, Oktavia RM, Meola A, Ahouzi O, Hoover-Watson H, Prot M, Delaune D, Cornelissen M, Deijs M, Meriaux V, Mouquet H, Simon-Lorière E, van der Hoek L, Lafaye P, Rey F, Buchrieser J, Schwartz O. Saunders N, et al. Among authors: simon loriere e. Nature. 2023 Dec;624(7990):207-214. doi: 10.1038/s41586-023-06761-7. Epub 2023 Oct 25. Nature. 2023. PMID: 37879362 Free PMC article.
Towards SARS-CoV-2 serotypes?
Simon-Loriere E, Schwartz O. Simon-Loriere E, et al. Nat Rev Microbiol. 2022 Apr;20(4):187-188. doi: 10.1038/s41579-022-00708-x. Nat Rev Microbiol. 2022. PMID: 35181769 Free PMC article.
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.
Tegally H, San JE, Cotten M, Moir M, Tegomoh B, Mboowa G, Martin DP, Baxter C, Lambisia AW, Diallo A, Amoako DG, Diagne MM, Sisay A, Zekri AN, Gueye AS, Sangare AK, Ouedraogo AS, Sow A, Musa AO, Sesay AK, Abias AG, Elzagheid AI, Lagare A, Kemi AS, Abar AE, Johnson AA, Fowotade A, Oluwapelumi AO, Amuri AA, Juru A, Kandeil A, Mostafa A, Rebai A, Sayed A, Kazeem A, Balde A, Christoffels A, Trotter AJ, Campbell A, Keita AK, Kone A, Bouzid A, Souissi A, Agweyu A, Naguib A, Gutierrez AV, Nkeshimana A, Page AJ, Yadouleton A, Vinze A, Happi AN, Chouikha A, Iranzadeh A, Maharaj A, Batchi-Bouyou AL, Ismail A, Sylverken AA, Goba A, Femi A, Sijuwola AE, Marycelin B, Salako BL, Oderinde BS, Bolajoko B, Diarra B, Herring BL, Tsofa B, Lekana-Douki B, Mvula B, Njanpop-Lafourcade BM, Marondera BT, Khaireh BA, Kouriba B, Adu B, Pool B, McInnis B, Brook C, Williamson C, Nduwimana C, Anscombe C, Pratt CB, Scheepers C, Akoua-Koffi CG, Agoti CN, Mapanguy CM, Loucoubar C, Onwuamah CK, Ihekweazu C, Malaka CN, Peyrefitte C, Grace C, Omoruyi CE, Rafaï CD, Morang'a CM, Erameh C, Lule DB, Bridges DJ, Mukadi-Bamuleka D, Park D, Rasmussen DA, Baker D, Nokes DJ, Ssemwanga D, Tshiabuila D, Amuzu DSY, Goedhals D,… See abstract for full author list ➔ Tegally H, et al. Among authors: simon loriere e. Science. 2022 Oct 7;378(6615):eabq5358. doi: 10.1126/science.abq5358. Epub 2022 Oct 7. Science. 2022. PMID: 36108049 Free PMC article.
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
Zhang L, Kempf A, Nehlmeier I, Cossmann A, Richter A, Bdeir N, Graichen L, Moldenhauer AS, Dopfer-Jablonka A, Stankov MV, Simon-Loriere E, Schulz SR, Jäck HM, Čičin-Šain L, Behrens GMN, Drosten C, Hoffmann M, Pöhlmann S. Zhang L, et al. Among authors: simon loriere e. Cell. 2024 Feb 1;187(3):596-608.e17. doi: 10.1016/j.cell.2023.12.025. Epub 2024 Jan 8. Cell. 2024. PMID: 38194966
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Boland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S; COVID-SER study group; Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Among authors: simon loriere e. bioRxiv [Preprint]. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873. bioRxiv. 2024. Update in: Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7 PMID: 38045308 Free PMC article. Updated. Preprint.
Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023.
Jeworowski LM, Mühlemann B, Walper F, Schmidt ML, Jansen J, Krumbholz A, Simon-Lorière E, Jones TC, Corman VM, Drosten C. Jeworowski LM, et al. Among authors: simon loriere e. Euro Surveill. 2024 Jan;29(2):2300740. doi: 10.2807/1560-7917.ES.2024.29.2.2300740. Euro Surveill. 2024. PMID: 38214083 Free PMC article.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Among authors: simon loriere e. Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7. Nat Commun. 2024. PMID: 38480689 Free PMC article.
Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
Lassaunière R, Polacek C, Utko M, Sørensen KM, Baig S, Ellegaard K, Escobar-Herrera LA, Fomsgaard A, Spiess K, Gunalan V, Bennedbæk M, Fonager J, Schwartz O, Planas D, Simon-Lorière E, Schneider UV, Sieber RN, Stegger M, Nielsen L, Hoppe M, Krause TG, Ullum H, Jokelainen P, Rasmussen M. Lassaunière R, et al. Among authors: simon loriere e. Lancet Infect Dis. 2023 Dec;23(12):e509-e510. doi: 10.1016/S1473-3099(23)00682-5. Epub 2023 Nov 7. Lancet Infect Dis. 2023. PMID: 37949089 No abstract available.
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C, Fernández I, Bruel T, de Melo GD, Prot M, Beretta M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, Staropoli I, Guivel-Benhassine F, Hieu T, Boullé M, Cervantes-Gonzalez M, Ungeheuer MN, Charneau P, van der Werf S, Agou F; French COVID Cohort Study Group; CORSER Study Group; Dimitrov JD, Simon-Lorière E, Bourhy H, Montagutelli X, Rey FA, Schwartz O, Mouquet H. Planchais C, et al. Among authors: simon loriere e. J Exp Med. 2022 Jul 4;219(7):e20220638. doi: 10.1084/jem.20220638. Epub 2022 Jun 15. J Exp Med. 2022. PMID: 35704748 Free PMC article.
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: simon loriere e. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962 Free PMC article.
118 results